TITLE:
Study of TRAVATAN in Subjects With Iris Pigmentation Changes

CONDITION:
Open-Angle Glaucoma

INTERVENTION:
Travoprost, 0.004% ophthalmic solution

SUMMARY:

      The purpose of this study was to monitor iris pigmentation changes over a 5-year period in
      patients with open-angle glaucoma or ocular hypertension. To be eligible for the study,
      these individuals must have experienced an iris pigmentation change while previously dosing
      with TRAVATAN.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: N/A to N/A
Criteria:

        Inclusion:

          -  Diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment
             dispersion component) or ocular hypertension;

          -  Has experienced an iris pigmentation change while dosing with TRAVATAN;

          -  Currently dosing with TRAVATAN;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion:

          -  Any form of glaucoma other than open-angle glaucoma (with or without a pigment
             dispersion or pseudoexfoliation component) or ocular hypertension;

          -  Not currently using TRAVATAN;

          -  Females of childbearing potential if pregnant, breast-feeding, or not using highly
             effective birth control measures;

          -  History of any severe ocular pathology (including severe dry eye);

          -  Other protocol-defined exclusion criteria may apply.
      
